Third-line systemic treatment for non-small cell lung cancer
This is a protocol for a Cochrane Review (Intervention). The objectives are as follows: In patients with advanced (Stage IIIB and IV) NSCLC with EGFR wild‐type, unknown status of EGFR, or with EGFR activating mutations ( Mountain 1997 ), to assess in terms of OS and PFS the clinical efficacy of thir...
Gespeichert in:
| Veröffentlicht in: | Cochrane database of systematic reviews 2014-09, Vol.2014 (9) |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 9 |
| container_start_page | |
| container_title | Cochrane database of systematic reviews |
| container_volume | 2014 |
| creator | Kim, Stefano C Paget-Bailly, Sophie Trinquart, Ludovic Calais, François Bonnetain, Franck Westeel, Virginie |
| description | This is a protocol for a Cochrane Review (Intervention). The objectives are as follows:
In patients with advanced (Stage IIIB and IV) NSCLC with EGFR wild‐type, unknown status of EGFR, or with EGFR activating mutations (
Mountain 1997
), to assess in terms of OS and PFS the clinical efficacy
of third‐line chemotherapy compared to placebo or best supportive care,
third‐line targeted therapy compared to placebo or best supportive care,
the third‐line combination of chemotherapy and targeted therapy compared to placebo or best supportive care; and
to assess the relative efficacy of third‐line chemotherapy compared to targeted therapy. |
| doi_str_mv | 10.1002/14651858.CD011291 |
| format | Article |
| fullrecord | <record><control><sourceid>pubmedcentral_cross</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6491211</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>pubmedcentral_primary_oai_pubmedcentral_nih_gov_6491211</sourcerecordid><originalsourceid>FETCH-LOGICAL-c2101-c43632876aee6d581e5dada9c44c58cf600120039e8965fae076e5fd874131903</originalsourceid><addsrcrecordid>eNpVkF9LwzAUxYMoOKcfwLd-gczcpEkTEEHqXxj4Mp9DTG-3SpuOpBP27W2ZE32593IO98fhEHINbAGM8RvIlQQt9aJ8YADcwAmZTRqdxNM_9zm5SOmTMaEML2bkdrVpYkXbJmCW9mnArvHZENENHYYhq_uYhT7Q1Lm2zTyOo92FdeZd8BgvyVnt2oRXP3tO3p8eV-ULXb49v5b3S-o5MKA-F0pwXSiHqCqpAWXlKmd8nnupfa0YAz4mMqiNkrVDViiUdaWLHAQYJubk7sDd7j46rPyYLLrWbmPTubi3vWvsfyc0G7vuv6zKDXCAEQAHgI99ShHr319gdurPHvuzx_7EN_0wY3g</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Third-line systemic treatment for non-small cell lung cancer</title><source>Cochrane Library</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>Kim, Stefano C ; Paget-Bailly, Sophie ; Trinquart, Ludovic ; Calais, François ; Bonnetain, Franck ; Westeel, Virginie</creator><creatorcontrib>Kim, Stefano C ; Paget-Bailly, Sophie ; Trinquart, Ludovic ; Calais, François ; Bonnetain, Franck ; Westeel, Virginie</creatorcontrib><description>This is a protocol for a Cochrane Review (Intervention). The objectives are as follows:
In patients with advanced (Stage IIIB and IV) NSCLC with EGFR wild‐type, unknown status of EGFR, or with EGFR activating mutations (
Mountain 1997
), to assess in terms of OS and PFS the clinical efficacy
of third‐line chemotherapy compared to placebo or best supportive care,
third‐line targeted therapy compared to placebo or best supportive care,
the third‐line combination of chemotherapy and targeted therapy compared to placebo or best supportive care; and
to assess the relative efficacy of third‐line chemotherapy compared to targeted therapy.</description><identifier>ISSN: 1465-1858</identifier><identifier>EISSN: 1465-1858</identifier><identifier>EISSN: 1469-493X</identifier><identifier>DOI: 10.1002/14651858.CD011291</identifier><language>eng</language><publisher>Chichester, UK: John Wiley & Sons, Ltd</publisher><subject>Medicine General & Introductory Medical Sciences</subject><ispartof>Cochrane database of systematic reviews, 2014-09, Vol.2014 (9)</ispartof><rights>Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. 2018 The Cochrane Collaboration</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c2101-c43632876aee6d581e5dada9c44c58cf600120039e8965fae076e5fd874131903</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,776,780,881,27903,27904</link.rule.ids></links><search><creatorcontrib>Kim, Stefano C</creatorcontrib><creatorcontrib>Paget-Bailly, Sophie</creatorcontrib><creatorcontrib>Trinquart, Ludovic</creatorcontrib><creatorcontrib>Calais, François</creatorcontrib><creatorcontrib>Bonnetain, Franck</creatorcontrib><creatorcontrib>Westeel, Virginie</creatorcontrib><title>Third-line systemic treatment for non-small cell lung cancer</title><title>Cochrane database of systematic reviews</title><description>This is a protocol for a Cochrane Review (Intervention). The objectives are as follows:
In patients with advanced (Stage IIIB and IV) NSCLC with EGFR wild‐type, unknown status of EGFR, or with EGFR activating mutations (
Mountain 1997
), to assess in terms of OS and PFS the clinical efficacy
of third‐line chemotherapy compared to placebo or best supportive care,
third‐line targeted therapy compared to placebo or best supportive care,
the third‐line combination of chemotherapy and targeted therapy compared to placebo or best supportive care; and
to assess the relative efficacy of third‐line chemotherapy compared to targeted therapy.</description><subject>Medicine General & Introductory Medical Sciences</subject><issn>1465-1858</issn><issn>1465-1858</issn><issn>1469-493X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><recordid>eNpVkF9LwzAUxYMoOKcfwLd-gczcpEkTEEHqXxj4Mp9DTG-3SpuOpBP27W2ZE32593IO98fhEHINbAGM8RvIlQQt9aJ8YADcwAmZTRqdxNM_9zm5SOmTMaEML2bkdrVpYkXbJmCW9mnArvHZENENHYYhq_uYhT7Q1Lm2zTyOo92FdeZd8BgvyVnt2oRXP3tO3p8eV-ULXb49v5b3S-o5MKA-F0pwXSiHqCqpAWXlKmd8nnupfa0YAz4mMqiNkrVDViiUdaWLHAQYJubk7sDd7j46rPyYLLrWbmPTubi3vWvsfyc0G7vuv6zKDXCAEQAHgI99ShHr319gdurPHvuzx_7EN_0wY3g</recordid><startdate>20140911</startdate><enddate>20140911</enddate><creator>Kim, Stefano C</creator><creator>Paget-Bailly, Sophie</creator><creator>Trinquart, Ludovic</creator><creator>Calais, François</creator><creator>Bonnetain, Franck</creator><creator>Westeel, Virginie</creator><general>John Wiley & Sons, Ltd</general><scope>AAYXX</scope><scope>CITATION</scope><scope>5PM</scope></search><sort><creationdate>20140911</creationdate><title>Third-line systemic treatment for non-small cell lung cancer</title><author>Kim, Stefano C ; Paget-Bailly, Sophie ; Trinquart, Ludovic ; Calais, François ; Bonnetain, Franck ; Westeel, Virginie</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c2101-c43632876aee6d581e5dada9c44c58cf600120039e8965fae076e5fd874131903</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Medicine General & Introductory Medical Sciences</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kim, Stefano C</creatorcontrib><creatorcontrib>Paget-Bailly, Sophie</creatorcontrib><creatorcontrib>Trinquart, Ludovic</creatorcontrib><creatorcontrib>Calais, François</creatorcontrib><creatorcontrib>Bonnetain, Franck</creatorcontrib><creatorcontrib>Westeel, Virginie</creatorcontrib><collection>CrossRef</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Cochrane database of systematic reviews</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kim, Stefano C</au><au>Paget-Bailly, Sophie</au><au>Trinquart, Ludovic</au><au>Calais, François</au><au>Bonnetain, Franck</au><au>Westeel, Virginie</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Third-line systemic treatment for non-small cell lung cancer</atitle><jtitle>Cochrane database of systematic reviews</jtitle><date>2014-09-11</date><risdate>2014</risdate><volume>2014</volume><issue>9</issue><issn>1465-1858</issn><eissn>1465-1858</eissn><eissn>1469-493X</eissn><abstract>This is a protocol for a Cochrane Review (Intervention). The objectives are as follows:
In patients with advanced (Stage IIIB and IV) NSCLC with EGFR wild‐type, unknown status of EGFR, or with EGFR activating mutations (
Mountain 1997
), to assess in terms of OS and PFS the clinical efficacy
of third‐line chemotherapy compared to placebo or best supportive care,
third‐line targeted therapy compared to placebo or best supportive care,
the third‐line combination of chemotherapy and targeted therapy compared to placebo or best supportive care; and
to assess the relative efficacy of third‐line chemotherapy compared to targeted therapy.</abstract><cop>Chichester, UK</cop><pub>John Wiley & Sons, Ltd</pub><doi>10.1002/14651858.CD011291</doi><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1465-1858 |
| ispartof | Cochrane database of systematic reviews, 2014-09, Vol.2014 (9) |
| issn | 1465-1858 1465-1858 1469-493X |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6491211 |
| source | Cochrane Library; EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection |
| subjects | Medicine General & Introductory Medical Sciences |
| title | Third-line systemic treatment for non-small cell lung cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-21T12%3A37%3A19IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmedcentral_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Third-line%20systemic%20treatment%20for%20non-small%20cell%20lung%20cancer&rft.jtitle=Cochrane%20database%20of%20systematic%20reviews&rft.au=Kim,%20Stefano%20C&rft.date=2014-09-11&rft.volume=2014&rft.issue=9&rft.issn=1465-1858&rft.eissn=1465-1858&rft_id=info:doi/10.1002/14651858.CD011291&rft_dat=%3Cpubmedcentral_cross%3Epubmedcentral_primary_oai_pubmedcentral_nih_gov_6491211%3C/pubmedcentral_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |